Novo Nordisk CEO Mike Doustdar warned investors that 2026 will see increased competition in key non-US markets following the loss of market exclusivity for its flagship GLP-1 products in several European and Asia-Pacific countries. Management indicated that gross margins in international operations could contract by up to 200 basis points as pricing pressures intensify and biosimilar entrants gain share. Despite these challenges, the company plans to offset margin erosion through cost synergies in its manufacturing network and by accelerating launches of next-generation compounds in its obesity and diabetes pipeline.

In a safety update, the U.S. Food and Drug Administration reported that its preliminary analysis of post-marketing reports and large outcome trials did not identify a statistically significant association between GLP-1 receptor agonists and suicidal ideation or behavior. The agency noted that event counts were small — fewer than 0.1% of all adverse-event submissions — and many reports lacked full clinical context. To strengthen its assessment, the FDA is conducting a meta-analysis across all GLP-1 trials and leveraging its Sentinel System database, with final recommendations expected by mid-year. The update has been positively received by analysts, who view it as reducing a key safety overhang on the class.

Following FDA approval of the first once-daily oral semaglutide formulation for chronic weight management, Novo Nordisk shares jumped nearly 19% over the subsequent four weeks. Investors have highlighted that the pill removes injection barriers for an estimated 30 million adults in the U.S. and Europe who have declined injectable therapy. Company guidance projects that the oral product could add more than $2 billion in incremental annual sales by 2027, representing a 10% uplift to the obesity franchise. Analysts have raised 2026–2028 EPS forecasts by an average of 5% to reflect the expanded addressable market and higher anticipated uptake.